Objective: The objective of this study is to determine the epidemiological effectiveness of a first-line antiretroviral regimen with HIV protease inhibitor for preventing recurrent malaria in children under the range of HIV prevalence levels and malaria transmission intensities encountered in sub-Saharan Africa.
measures in Africa has steadily improved with expanded access to potent combination drug regimens [2] . WHOrecommended first-line antiretroviral regimens for children currently include a dual-nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) with either an HIV nonnucleoside reverse transcriptase inhibitor (NNRTI), for children over 3 years of age, or an HIV protease inhibitor, for children under 3 years of age [3, 4] . The choice of NNRTIs or protease inhibitor based HAART first-line antiretroviral drug regimens is a topic of current deliberation, as each drug has its own pros and cons [4] [5] [6] . For instance, although generic formulations of NNRTIs are more often available and relatively inexpensive, viral mutation can readily induce resistance to nearly all currently available drugs in the NNRTI class [6, 7] . In contrast, although protease inhibitors are more expensive, they are becoming increasingly available and have higher genetic barriers to resistance [7, 8] . Here, we explore another factor for consideration in the decision of which antiretroviral regimen should be implemented. Specifically, the interaction between protease inhibitors and antimalarial treatments has potential direct antimalarial effects and indirect benefits in terms of extending the posttreatment prophylactic effect of antimalarials [5, 9, 10] .
Similarly to HIV, expanding availability of and advances in antimalarial treatments, namely the use of artemisininbased combination therapy (ACT), has reduced the global morbidity and mortality attributed to Plasmodium falciparum. The most widely adopted ACT, artemetherlumefantrine, combines a short-acting artemisinin with a longer acting, but less potent partner drug, lumefantrine. Building on the in-vitro antimalarial activity observed with protease inhibitors, a recent clinical trial in a high malaria endemic region of Uganda has shown that HIVinfected children treated with protease inhibitor based HAART have a 41% lower incidence of malaria than children on NNRTI-based HAART. Notably, the major impact of the HIV protease inhibitors appears to be an extension of the posttreatment prophylactic effect of artemether-lumefantrine for the prevention of recurrent malaria as compared with those children on NNRTIbased HAART [5, 9] . This extension likely occurs due to protease inhibitor mediated inhibition of lumefantrine metabolism, and subsequent enhanced exposure over time [10] . The epidemiological impact of extended posttreatment prophylactic effect of artemether-lumefantrine attributable to protease inhibitors has yet to be evaluated at the population level.
Using clinical and epidemiological data from a clinical trial regarding the effect of protease inhibitors as compared with NNRTIs on the incidence of malaria in HIV-infected children in highly endemic regions [5] , we evaluated the population-level effectiveness of a firstline antiretroviral regimen with protease inhibitors for reducing the health burden of recurrent malaria among children in sub-Saharan Africa in areas with varying levels of HIV and malaria prevalence. For this analysis, we developed a dynamic model of malaria transmission that takes into account both HIV-infected and HIV-uninfected children. Given the uncertainty of predictions in low malaria transmission settings [entomological inoculation rates (EIRs) from one infectious bite per person per year (ibpppy) to 10 ibpppy] [11] , and because the majority of the 61% of sub-Saharan Africans who live in rural areas experience an EIR more than 10 ibpppy (in addition to the fact that urban sub-Saharan Africans experience an average EIR >10 ibpppy) [12] , we evaluated a range of EIRs from 10 ibpppy to the previously estimated EIR of the Ugandan clinical study site of up to 562 ibpppy [13] . Finally, we assessed the epidemiological effectiveness of protease inhibitors on malaria burden under varying newborn HIV prevalence and varying malaria transmission intensities. We found that in areas where HIVand malaria are coendemic, the extended posttreatment prophylactic effect of artemether-lumefantrine in the context of protease inhibitor based regimens is a significant benefit that should be factored into the decision regarding the selection of first-line antiretroviral therapy treatment to prescribe in malaria coendemic regions.
Materials and methods
To estimate the effectiveness of the extended posttreatment prophylactic effect of artemether-lumefantrine in reducing the health burden of recurrent malaria in the setting of protease inhibitor-based HAART, we developed a dynamic model of malaria transmission in sub-Saharan Africa.
From a Ugandan clinical study, data were obtained comparing the incidence of uncomplicated malaria in HIV-infected children on protease inhibitor based vs. NNRTI-based regimens [5] . On the basis of these data, we constructed distributions for the duration of the posttreatment prophylactic effect (for preventing recurrent malaria) of the antimalarial drug, lumefantrine, with and without protease inhibitors ( Figure S2 The outcomes measured, for all HIV-positive and HIVnegative children, include annual malaria incidence, malaria transmission intensity (as measured by the EIR) and disease burden measured through disability-adjusted life-years (DALYs). DALYs for a disease are the combined sums of both the years of life lost due to premature mortality and the years lost due to disability over an entire population [14] .
We conservatively determined the health benefit of protease inhibitor based HAART only with respect to malaria, and only with respect to the extended posttreatment prophylactic effect derived from the combination of protease inhibitor based HAART and artemether-lumefantrine, and do not consider any HIVrelated benefit associated directly with the choice of HAART regimen.
To reflect the varying malaria transmission intensity and varying newborn HIV prevalence levels that occur in different locations across sub-Saharan Africa, we considered EIR ranging from 10 to 562 ibpppy, and newborn HIV prevalence ranging from 0.01 to 6.7% [2, 15] . We limited our EIR range to a maximum of 562 ibppy due to concerns of overstating effects of protease inhibitor based HAART at higher EIRs, as well as a recognition that the overwhelming majority of sub-Saharan Africa is situated in EIR ranges below this threshold [16] . To reflect varying availability of protease inhibitors in sub-Saharan Africa, we varied the proportion of children who are treated with NNRTI and protease inhibitor based HAART from 0 to 1 in intervals of 0.1.
Mathematical model
We developed a dynamic model that couples malarial infection dynamics of humans and mosquitoes parameterized from the epidemiological and clinical studies, including a recent clinical trial in Uganda [5] . The population size of mosquitoes determines malaria transmission intensity, that is the average number of infectious mosquitoes bites received per child. We divided the mosquito population into three compartments, Ms susceptible adult, M E exposed adult and M I infected adults. We assumed the total mosquito population M to be constant such that M ¼ M S þM E þM I . Mosquito demography was parameterized from an entomological study of Anophelis gambiae [17] . We denoted t M as the duration of extrinsic incubation of malaria in mosquitoes, c as the biting rate of the mosquitoes, I þ as the number of malaria-infected children who are also HIV-infected and I À as the malaria-infected children who are HIV-negative. The probability of malaria transmission to a mosquito, b H ðI þ þ I À Þ=H, was the product of the probability of a mosquito becoming infectious upon biting an infected human, b H , and the proportion of infected children, where H is the total number of humans. The force of infection for the mosquito population was given by:
The child population was divided into an HIV-infected group, which was indicated by a þ superscript and an HIV-negative group represented by a -superscript. We considered that all newborns R m have maternally acquired immunity against malaria that wanes at a rate d M . The rate at which a susceptible individual S acquires infection was given by the force of infection:
Children who recovered from malaria did so at the rate g.
The rate at which a recovered child becomes susceptible again, that is the rate at which the posttreatment prophylactic effect of artemether-lumefantrine wanes, was denoted by d. We take into account that protease inhibitors extend the posttreatment prophylactic effect of artemether-lumefantrine, likely due to protease inhibitor mediated inhibition of lumefantrine metabolism [10] . Parameter values, associated distributions and sources are provided in Table 1 [14, [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] . Model equations are presented in the Webappendix.
The entomological inoculation rate
The EIR is defined as the number of infectious bites on a human annually. The average EIR in urban settings in Africa has been estimated as 18.8 ibpppy and in rural settings as 112 ibpppy [11, 16] , with upper estimates at the Ugandan clinical study site of 562 ibpppy (observations ranged from 379 to 562 ibpppy) [5, 13, 34] . We consider EIR values over this range, varying the EIR from a low malaria transmission setting of 10 ibpppy to an intermediate EIR of 112 ibpppy estimated from several locations in sub-Saharan Africa [16] , to the observed high malaria transmission intensity of the Ugandan clinical study site of 562 ibpppy (although more recent estimates have suggested a lower EIR at this site) [5, 13, 34] . Details pertaining to the EIR calculation are available in the Webappendix.
Health outcomes
To determine the direct and indirect benefit of protease inhibitor based HAART on death and disability due to malaria, we measured the health outcomes in DALYs [35] , with a newborn HIV prevalence (a) corresponding to an estimated maximum newborn HIV prevalence of 6.7% (Table 1) , the average newborn HIV prevalence of sub-Saharan Africa of 1.3% [36] and an estimated minimum newborn HIV prevalence of 0.01%. In addition, we varied the EIR to examine a lower rate of 10 ibpppy, the estimated average EIR of 112 ibpppy [16] and the highest EIR encountered at the Ugandan clinical study site of 562 ibpppy [13] . We calculated timediscounted DALYs lost to malaria, severe malaria, cerebral malaria, neurological sequelae and severe malarial anaemia over a duration of 5 years. To determine the net DALYs saved, total DALYs lost under the NNRTIbased HAART scenario were subtracted from the protease inhibitor based HAART scenario. Parameter values for the calculation of the DALYs are contained in Table 1 . Age-weighting parameter 0.04 [14] DALY, disability-adjusted life-year.
Sensitivity analysis
To quantify the contribution of each model parameter to the variability of the outcome measures, we calculated the partial rank correlation coefficients (PRCCs) between the input and output variables [37] . Specifically, a positive PRCC implies that when the value of an input variable increases, the output variable increases, whereas a negative PRCC implies that an increase in an input variable decreases the output variable (Table S2 , http:// links.lww.com/QAD/A618). In addition, the magnitude of a PRCC is a measure of the contribution of an input variable to the uncertainty of an output variable. For this purpose, we used Latin Hypercube Sampling to draw input parameters from their probability distributions as summarized in Table 1 .
Results
To determine the impact of the artemether-lumefantrine mediated extension of the posttreatment prophylactic effect of protease inhibitors on malaria incidence, we simulated malaria transmission with a dynamic model under nine scenarios of low, intermediate and high conditions of both HIV prevalence [36] and malaria transmission [13, 16] , respectively. We found that in the range of malaria transmission intensities in our model, the use of HIV protease inhibitors at the intermediate (1.3%) and high (6.7%) HIV prevalence scenarios significantly reduced malaria incidence and saved DALYs ( Table 2) .
With an EIR of 10 ibpppy, and all the HIV-infected children treated with NNRTI-based HAART, under the scenarios of low (0.01%), intermediate (1.3%) and high (6.7%) newborn HIV prevalence, there were 2.43, 2.54 and 2.63 annual malaria incidence per person ( Table 2) . Switching HIV treatment from NNRTI-based HAART to protease inhibitor based HAARTaverted between 0.03 to 25.5 annual incidences of malaria per 1000 people, depending on the HIV prevalence ( For the EIR of the Ugandan clinical study site of 562 ibpppy, when HIV-infected children are treated with NNRTIs, the annual malaria incidence per person (for newborn HIV prevalence of 0.01, 1.3 and 6.7%) was close to 6 ( Table 2 ). Using protease inhibitor based HAART for low (0.01%), intermediate (1.3%) and high (6.7%) newborn HIV prevalence, switching HIV treatment to protease inhibitor based HAART averted 1042, 1043 and 1043 annual incidences of malaria per 1000 HIV-infected children.
Sensitivity analysis showed that for all scenarios of HIV prevalence and malaria transmission intensities, the primary parameters that determine malaria incidence were mosquito to human transmission (b M ) and the duration of posttreatment prophylactic effect (d PI ) (Fig. 3) . As both the malaria transmission intensity and HIV prevalence increase, the sensitivity of the projections of the posttreatment prophylactic effect (d PI ) also increases ( Fig. 3 ).
Discussion
Our transmission modelling analysis predicts that the use of protease inhibitor based regimens in the setting of artemether-lumefantrine treatment would substantially reduce the health burden of malaria in HIV-infected sub-Saharan African children. Treating HIV-infected children with protease inhibitors achieves a reduction in annual malaria incidence, saves DALYs and lowers annual number of infectious bites per person. With the reduction in malaria transmission that occurs, there would also be an indirect impact on the incidence of malaria to the population overall, even to individuals who are not themselves treated or HIV infected. Table S2 , http://links.lww.com/QAD/A618).
The predictions of our model are in line with observed clinical data and intervention studies [38] . Our predicted 6 annual malaria incidence per person for an EIR of 562 ibpppy is within the empirical range of 3.5-6.5 observed at the clinical study site in Tororo, Uganda, for HIVuninfected children [34] . Because we only measured the benefit of protease inhibitors, our model's predicted annual malaria incidence per person for HIV-infected children was above the incidence levels from the Ugandan clinical study [5] . This is due, in part, to compounding protective factors in the Ugandan clinical study, such as the significant antimalarial benefit that all HIV infected children received from the antimicrobial, trimethoprimsulfamethoxazole [39] . In addition, the clinical study on the effect of protease inhibitors on malaria incidence determined that HIV-infected children treated with protease inhibitor-based HAARTendure 0.93 less annual malaria incidence per person [5] in comparison to their NNRTI-based HAART counterparts. Using the previously estimated EIR of 562 ibpppy from the clinical study site [13] , our model predicts that HIV-infected children treated with protease inhibitor-based HAART endure 278-1043 less annual malaria incidence per 1000 HIV infected people in comparison to their NNRTIbased HAART counterparts. Furthermore, our model's predictions of 0.002-4.3 annual DALYs saved per 1000 children are comparable to alternative studies on the benefit of protease inhibitor-based HAART for the prevention of malaria that predict 2.15 annual DALYs saved per 1000 children [40] .
The annual DALYs saved, as a result of the indirect benefit of treating HIV-infected children with protease inhibitorbased HAART, is substantial and comparable to direct malaria interventions, such as the intermittent presumptive treatment of malaria in pregnancy [41] . Our analysis was conservative in that we focused on the impact of an HIV protease inhibitor-mediated extension of the lumefantrine posttreatment prophylactic effect in the context of artemether-lumefantrine treatment. However, emerging data suggest that protease inhibitor-based HAART may have additional benefits on malaria, including activity against gametocytes and transmission-blocking activity [42, 43] . In addition, in contrast to the extension of prophylactic activity seen with lopinavir-ritonavir, the use of artemether-lumefantrine in the setting of efavirenz-based HAART is associated with a significant reduction in lumefantrine exposure [44, 45] . A further benefit of switching from NNRTIs to protease inhibitors is that protease inhibitors have been found to provide a higher barrier to the development of drug-resistance in HIV [8] .
Increasing evidence supports the efficacy of protease inhibitor-based HAART in the treatment of HIVinfected children and adults in Africa [4, 8, 46, 47] . Our model suggests an additional benefit on the prevention of malaria at any level of malaria transmission, though the magnitude of the marginal benefit of protease inhibitors for a community is sensitive to the level of endemic malaria in a particular setting. Consequently, protease inhibitors may be deemed both effective and costeffective in settings with high intensities of malaria and less worthwhile in settings of lower intensity, given inevitable budgetary constraints. For example, areas, such as much of Uganda, burdened with devastating coepidemics of malaria and HIV would benefit most dramatically from the switch to protease inhibitors, whereas the marginal benefits of protease inhibitors for urban settings in which malaria tends to be less prevalent would be less impactful.
Mathematical models of real-world infectious diseases inevitably involve simplifications. For example, in our analysis, we did not account for multiple malaria strains, vector subspecies, potential impacts upon gametocyte rates or independent effects of other prevention measures. For example, as both HAART groups were receiving trimethoprim-sulfamethoxazole prophylaxis, we were unable to discern the independent effects of trimethoprim-sulfamethoxazole on the risk of recurrent malaria. Future models may attempt to model this effect using data from other African populations receiving prophylaxis in the absence of HAART. With respect to HIV, the higher genetic barrier to drug resistance would likely tip the balance further in the direction of protease inhibitors over NNRTIs. Our model is calibrated specifically to describe transmission of the most virulent malaria parasite, Plasmodium falciparum. However, malaria species such as Plasmodium vivax are also treated with artemetherlumefantrine, and protease inhibitors have been shown to have similarly strong in-vitro direct antimalarial effects [48, 49] . Although clinical data on HAART and artemether-lumefantrine are lacking, modest adjustments to our model parameterization could help to predict potential benefits of this regimen in coendemic settings.
In summary, HIV-infected children that use protease inhibitor based HAART have a reduced burden of malaria due to extended postprophylactic effect of artemetherlumefantrine. Our model shows that the extended postprophylactic effect of artemether-lumefantrine would effectively reduce malaria incidence and prevalence of HIV-infected children on protease inhibitors from intermediate to high HIV prevalence levels. Consequently, in settings in which artemether-lumefantrine is the principal ACT used in the treatment of malaria, protease inhibitor based HAART may be a preferred regimen for HIV treatment in coendemic settings.
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